prod:prod_dcx-login
Xpert® Xpress GBS
Qualitative real-time PCR test providing accurate intrapartum detection of Group B Streptococcus in labor/delivery
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
Tests
XPRSGBS-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
In the U.S., Group B Streptococcus (GBS) remains a leading cause of early-onset neonatal sepsis. Rates of maternal colonization have not changed, but universal antenatal screening at 36–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early onset disease.1,2
Challenges remain, including:
Challenges remain, including:
- The latest ACOG practice guidelines recommend universal antepartum screening along with intrapartum where indicated based on risk.
- GBS colonization can be transient 2 and identifying women colonized at the time of delivery can be challenging.
- Some women present at the delivery room with unknown GBS status.
1 ASM, March 2020, Guidelines for the Detection and Identification of Group B Streptococcus - Revised Guidelines from CDC, 2020.
2 ACOG Committee Opinion No. 797: Prevention of Group B Streptococcal Early-Onset Disease in Newborns. Obstet Gynecol. 2020 Feb;135(2):e51-e72.
2 ACOG Committee Opinion No. 797: Prevention of Group B Streptococcal Early-Onset Disease in Newborns. Obstet Gynecol. 2020 Feb;135(2):e51-e72.
The Solution
The Xpert® Xpress GBS test is intended to aid in the diagnosis of GBS colonization intrapartum to identify candidates for antibiotic prophylaxis. With results in less than an hour, the Xpert® Xpress GBS test delivers 93.5% sensitivity and 95.5% specificity.
Not just a solution, a complete solution - The Xpert® GBS LB XC test and the Xpert Xpress GBS test are aligned with ACOG criteria for antenatal and intrapartum testing, respectively.
On-demand molecular testing — an ideal solution:
Not just a solution, a complete solution - The Xpert® GBS LB XC test and the Xpert Xpress GBS test are aligned with ACOG criteria for antenatal and intrapartum testing, respectively.
On-demand molecular testing — an ideal solution:
- System designed with Early Assay Termination (EAT) which can reduce the test time for positive results to approximately 30 minutes*
- As soon as positive sample is confirmed, software concludes test and reports immediately
- Random access ensures any test on the menu can be run anytime, without the need to batch
* Otherwise, the full test runtime is approximately 42 minutes.
The Impact
- Identify GBS colonization status at the time of labor (intrapartum) of low-risk women at term with unknown GBS status.
- Xpert Xpress GBS test is designed to run in the clinical lab 24 hours a day, 365 days a year.
- Fast and easy-to-interpret results enable adequate Intrapartum Antibiotic Prophylaxis (IAP) delivered to mothers with unknown status.
Related Products
Xpert CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
Xpert GBS LB XC
Detection of Group B Streptococcus with dual target with results within one hour
Xpert Xpress MVP
Multiplex vaginal panel that enables results within 60 minutes from a single specimen for Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis
Xpert TV
The First MolecularTrichomonas VaginalisTest for Both Women and Men